title: Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis.
abstract: Massive hemoptysis is a common complication in patients with cystic fibrosis (CF) and is associated with significant morbidity and mortality. Conventional treatment with antibiotic therapy and early bronchial artery embolization (BAE) is usually successful in achieving hemostasis in the majority of patients. Recombinant activated factor VII (rFVIIa), originally developed for use in patients with hemophilia, has emerged as a general hemostatic agent that is potentially useful in the management of many life-threatening bleeding conditions. In this article, we present four patients with CF lung disease and massive hemoptysis who were treated successfully with rFVIIa. We suggest that in patients with CF who present with massive hemoptysis, the use of rFVIIa can be considered in patients with refractory hemoptysis despite conventional therapy or as a temporizing therapy when BAE is not immediately available.
authors: Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors: Edmund M T
authors: EMT
authors: Lau
authors: Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors: Veronica
authors: V
authors: Yozghatlian
authors: Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors: Chris
authors: C
authors: Kosky
authors: Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors: Carmel
authors: C
authors: Moriarty
authors: Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors: Ruth
authors: R
authors: Dentice
authors: Department of Radiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors: Richard
authors: R
authors: Waugh
authors: Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors: Paul J
authors: PJ
authors: Torzillo
authors: Woolcock Institute of Medical Research and University of Sydney, Sydney, NSW, Australia; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia. Electronic address: peterb@med.usyd.edu.au.
authors: Peter T
authors: PT
authors: Bye
mesh_terms: D000328:Adult; D003550:Cystic Fibrosis / Q000150:complications*; D004621:Embolization, Therapeutic; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006469:Hemoptysis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa